Atterx Biotherapeutics is focused on addressing the critical issue of antibiotic resistance, which has led to a rise in infections that are increasingly difficult to treat. The company is developing innovative solutions aimed at preventing and treating infections caused by antibiotic-resistant bacteria. Their lead product, GN-4474, targets Gram-negative bacterial infections, while C-1205 is designed to combat catheter-associated urinary tract infections. These products are part of Atterx's commitment to tackling the growing threat of antimicrobial resistance, which is projected to result in a significant increase in annual deaths by 2050.

The company recognizes the urgent need for new therapeutic options as traditional antibiotics become less effective due to overuse and misuse. Atterx Biotherapeutics is dedicated to advancing its pipeline of products that aim to restore the efficacy of treatments for infections that were once easily manageable. By focusing on novel approaches to combat antibiotic resistance, Atterx is positioning itself as a key player in the fight against this global health crisis, ultimately striving to save lives and improve patient outcomes in the face of evolving bacterial threats.

United States

Proprietary products for the prevention and treatment of multi-drug resistant Gram negative bacterial infections.

Atterx Biotherapeutics

Company Details